HUP0100437A3 - Therapeutic formulation for administering tolterodine with controlled release - Google Patents

Therapeutic formulation for administering tolterodine with controlled release

Info

Publication number
HUP0100437A3
HUP0100437A3 HU0100437A HUP0100437A HUP0100437A3 HU P0100437 A3 HUP0100437 A3 HU P0100437A3 HU 0100437 A HU0100437 A HU 0100437A HU P0100437 A HUP0100437 A HU P0100437A HU P0100437 A3 HUP0100437 A3 HU P0100437A3
Authority
HU
Hungary
Prior art keywords
controlled release
therapeutic formulation
tolterodine
administering
administering tolterodine
Prior art date
Application number
HU0100437A
Other languages
English (en)
Original Assignee
Pharmacia And Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0100437(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pharmacia And Upjohn Ab filed Critical Pharmacia And Upjohn Ab
Publication of HUP0100437A2 publication Critical patent/HUP0100437A2/hu
Publication of HUP0100437A3 publication Critical patent/HUP0100437A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HU0100437A 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release HUP0100437A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation

Publications (2)

Publication Number Publication Date
HUP0100437A2 HUP0100437A2 (hu) 2002-05-29
HUP0100437A3 true HUP0100437A3 (en) 2002-08-28

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100437A HUP0100437A3 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Country Status (31)

Country Link
US (1) US6770295B1 (hu)
EP (2) EP1039882B1 (hu)
CN (1) CN1239152C (hu)
AP (1) AP1529A (hu)
AR (1) AR029311A1 (hu)
AT (1) ATE487471T1 (hu)
AU (1) AU745190B2 (hu)
BG (1) BG65168B1 (hu)
CA (1) CA2311755C (hu)
CY (1) CY1111088T1 (hu)
CZ (1) CZ302630B6 (hu)
DE (1) DE69942928D1 (hu)
DK (1) DK1039882T3 (hu)
EA (1) EA002720B1 (hu)
GE (1) GEP20043354B (hu)
HK (1) HK1034664A1 (hu)
HU (1) HUP0100437A3 (hu)
ID (1) ID25824A (hu)
IL (1) IL136294A (hu)
IS (1) IS2976B (hu)
ME (1) ME00850B (hu)
MY (1) MY127946A (hu)
NO (1) NO329830B1 (hu)
NZ (1) NZ504618A (hu)
OA (1) OA11636A (hu)
PT (1) PT1039882E (hu)
SI (1) SI1039882T1 (hu)
SK (1) SK287111B6 (hu)
TR (1) TR200001998T1 (hu)
UA (1) UA72882C2 (hu)
WO (1) WO2000012069A1 (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
SK6412002A3 (en) * 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
MXPA04003866A (es) * 2001-11-09 2004-07-08 Pharmacia Ab Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
CA2509605C (en) * 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
PL377995A1 (pl) * 2003-01-22 2006-02-20 Pfizer Health Ab Zmniejszona dawka tolterodyny i innych środków przeciwmuskarynowych do leczenia zaburzeń układu moczowego
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
JP5610663B2 (ja) 2003-11-04 2014-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの１日１回剤形
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
DE602006016934D1 (de) 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
EP3095447B1 (en) 2006-02-03 2021-11-24 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
PT2037936E (pt) 2006-06-21 2014-09-04 Opko Renal Llc Método de tratamento e prevenção do hiperparatiroidismo secundário
US20100144684A1 (en) 2007-04-25 2010-06-10 Proventiv Therapeutics, Inc. Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
CN104523707B (zh) 2007-04-25 2022-08-26 欧普科Ip 控股Ii 有限公司 包含维生素d化合物和蜡质载体的口服控释组合物
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
WO2009003724A1 (en) * 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
KR101685031B1 (ko) 2008-04-02 2016-12-09 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
CN103153294B (zh) * 2010-08-03 2015-07-29 久光制药株式会社 贴附剂及其粘着力增强方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
CR20170085A (es) 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ZA933349B (en) * 1992-05-13 1994-06-15 Alza Corp Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
WO1996012477A1 (en) 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence

Also Published As

Publication number Publication date
CA2311755A1 (en) 2000-03-09
IL136294A0 (en) 2001-05-20
ATE487471T1 (de) 2010-11-15
CZ20001924A3 (cs) 2001-04-11
AR029311A1 (es) 2003-06-25
ID25824A (id) 2000-11-09
WO2000012069A1 (en) 2000-03-09
TR200001998T1 (tr) 2001-01-22
GEP20043354B (en) 2004-04-13
HUP0100437A2 (hu) 2002-05-29
AU5891899A (en) 2000-03-21
CZ302630B6 (cs) 2011-08-10
EA002720B1 (ru) 2002-08-29
HK1034664A1 (en) 2001-11-02
ME00850B (me) 2008-08-07
IS2976B (is) 2017-07-15
IL136294A (en) 2004-02-08
IS5537A (is) 2000-06-15
NO329830B1 (no) 2011-01-03
AP2000001823A0 (en) 2000-06-30
CA2311755C (en) 2010-03-23
SI1039882T1 (sl) 2011-01-31
AP1529A (en) 2006-01-03
NO20002977L (no) 2000-06-09
BG65168B1 (bg) 2007-05-31
SK7492000A3 (en) 2001-02-12
CN1287484A (zh) 2001-03-14
DK1039882T3 (da) 2011-01-24
UA72882C2 (uk) 2005-05-16
MY127946A (en) 2007-01-31
PT1039882E (pt) 2011-01-03
NO20002977D0 (no) 2000-06-09
CY1111088T1 (el) 2015-06-11
CN1239152C (zh) 2006-02-01
SK287111B6 (sk) 2009-12-07
NZ504618A (en) 2002-09-27
EP1039882A1 (en) 2000-10-04
OA11636A (en) 2004-09-03
EP2153825A1 (en) 2010-02-17
BG104476A (en) 2000-12-29
EA200000468A1 (ru) 2000-12-25
US6770295B1 (en) 2004-08-03
EP1039882B1 (en) 2010-11-10
AU745190B2 (en) 2002-03-14
DE69942928D1 (de) 2010-12-23

Similar Documents

Publication Publication Date Title
IL136294A0 (en) Therapeutic formulation for administering tolterodine with controlled release
IL143496A0 (en) Controlled release formulation comprising gnrh-ii
PL342515A1 (en) Drug administering device
GB2323531B (en) Therapeutic formulations
HK1019142A1 (en) Drug composition with controlled drug release rate
HUP0003840A3 (en) Controlled released medical formulation
IL138192A0 (en) Controlled release oral dosage forms
IL156414A0 (en) Therapeutic formulation for administering tolterodine with controlled release
PL325509A1 (en) Therapeutic agent for oral administration
GB9812662D0 (en) Therapeutic use
GB9810920D0 (en) Therapeutic use
GB9816897D0 (en) Therapeutic use
SI1117421T1 (en) Methods for therapeutic vaccination
GB9821179D0 (en) Therapeutic use
GB9811624D0 (en) Therapeutic use
GB2341319B (en) Use of compounds in the preparation of a medicament for the therapeutic treatment of a wasting syndrome
GB9404544D0 (en) Controlled release formulation
GB9812617D0 (en) Therapeutic use
GB9812612D0 (en) Therapeutic use
GB9812666D0 (en) Therapeutic use
GB9812669D0 (en) Therapeutic use
GB9801581D0 (en) Therapeutic use
GB9812661D0 (en) Therapeutic use
GB9812620D0 (en) Therapeutic use
GB9812618D0 (en) Therapeutic use

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished